Icon Plc $ICLR Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund boosted its holdings in shares of Icon Plc (NASDAQ:ICLR) by 180.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 224,785 shares of the medical research company’s stock after purchasing an additional 144,525 shares during the period. New York State Common Retirement Fund owned approximately 0.28% of Icon worth $39,337,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in ICLR. Tributary Capital Management LLC increased its stake in Icon by 84.5% in the 3rd quarter. Tributary Capital Management LLC now owns 11,752 shares of the medical research company’s stock valued at $2,057,000 after buying an additional 5,381 shares during the period. Stephens Investment Management Group LLC boosted its holdings in shares of Icon by 15.7% in the third quarter. Stephens Investment Management Group LLC now owns 480,104 shares of the medical research company’s stock valued at $84,018,000 after acquiring an additional 65,264 shares in the last quarter. Hudson Edge Investment Partners Inc. increased its stake in shares of Icon by 12.4% during the third quarter. Hudson Edge Investment Partners Inc. now owns 200,739 shares of the medical research company’s stock worth $35,129,000 after acquiring an additional 22,164 shares during the period. SeaBridge Investment Advisors LLC purchased a new position in Icon during the third quarter worth about $2,589,000. Finally, Trinity Street Asset Management LLP lifted its position in Icon by 3.5% in the third quarter. Trinity Street Asset Management LLP now owns 870,973 shares of the medical research company’s stock valued at $152,420,000 after purchasing an additional 29,558 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Trading Down 3.0%

Shares of ICLR stock opened at $180.25 on Friday. Icon Plc has a fifty-two week low of $125.10 and a fifty-two week high of $211.00. The stock has a market cap of $14.56 billion, a P/E ratio of 24.39, a P/E/G ratio of 3.93 and a beta of 1.26. The business has a fifty day simple moving average of $183.96 and a 200-day simple moving average of $176.40. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Bank of America cut Icon from a “buy” rating to a “neutral” rating and set a $195.00 target price on the stock. in a research report on Monday, December 15th. UBS Group set a $220.00 price objective on Icon in a report on Friday, October 24th. BMO Capital Markets began coverage on Icon in a report on Thursday, November 13th. They issued a “market perform” rating and a $175.00 target price for the company. Zacks Research upgraded shares of Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 25th. Finally, Truist Financial reiterated a “hold” rating and issued a $222.00 price target (down previously from $231.00) on shares of Icon in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $200.60.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.